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Introduction: Nodal status is considered to be one of the most reli-
able indicators of the prognosis in patients with lung cancer and thus 
is indispensable in determining the optimal therapeutic options. We 
sought to determine whether the current nodal (N) descriptors should 
be maintained or revised for the next edition (8th) of the International 
Lung Cancer Staging System.
Methods: The new International Association for the Study of Lung 
Cancer lung cancer database was created from 94,708 patients diag-
nosed as having lung cancer between 1999 and 2010. Among these, 
38,910 and 31,426 patients with non–small-cell lung carcinoma 
were available for an analysis of the clinical (c)N and pathological 
(p)N status, respectively. The anatomical location of lymph node 
involvement was deﬁned by either the Naruke (for Japanese data) 
or American Thoracic Society (for non-Japanese data) nodal charts. 
Survival was calculated by the Kaplan–Meier method, and prognos-
tic groups were assessed by a Cox regression analysis.
Results: The current N0 to N3 descriptors for both the cN and pN 
status consistently separated prognostically distinct groups. The 5-year 
survival rates according to the cN and pN status were 60% and 75% 
(N0), 37% and 49% (N1), 23% and 36% (N2), and 9% and 20% (N3), 
respectively. The differences in survival between all neighboring nodal 
categories were highly signiﬁcant for both the cN and pN status. With 
regard to pathological staging, additional analyses regarding the prog-
nosis were performed by further dividing N1 into N1 at a single sta-
tion (N1a) and N1 at multiple stations (N1b); N2 into N2 at a single 
station without N1 involvement (“skip” metastasis, N2a1), N2 at a 
single station with N1 involvement (N2a2), and N2 at multiple sta-
tions (N2b). The survival curves for N1b and N2a2 overlapped each 
other, and N2a1 had numerically a better prognosis than N1b, although 
the difference was not signiﬁcant. Geographic difference in N-speciﬁc 
prognosis was observed for both c-settings and p-settings. This might 
have been because of the difference in the used nodal map, surgical 
technique, and pathologist’s handling of the resected specimen.
Conclusions: Current N descriptors adequately predict the prognosis 
and therefore should be maintained in the forthcoming staging sys-
tem. Furthermore, we recommend that physicians record the number 
of metastatic lymph nodes (or stations) and to further classify the N 
category using new descriptors, such as N1a, N1b, N2a, N2b, and 
N3, for further testing.
Key Words: Lung cancer, Lung cancer staging, N component, N descrip-
tors, Tumor, node, metastasis classiﬁcation, Lymph node metastasis.
(J Thorac Oncol. 2015;10: 1675–1684)
The cancer staging classiﬁcation describes the anatomi-cal extent of malignant tumors in terms of three compo-
nents: primary tumor (T), nodal status for metastasis (N), and 
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metastasis at the distant organs (M). The TNM classiﬁcation has 
been revised periodically by both the Union for International 
Cancer Control (UICC) and the American Joint Committee on 
Cancer (AJCC) for epithelial and nonepithelial solid tumors of 
various organs.1,2 For most organs, a revision is proposed by the 
AJCC to the UICC as an agenda item created by the “organ task 
force” of the AJCC. However, lung cancer has a unique process 
of revision, in which the International Association for the Study 
of Lung Cancer (IASLC) has taken the initiative to develop 
proposals for revisions based on a newly collected large data 
set of their own and meticulous statistical analyses. This truly 
global, multidisciplinary effort has been termed the “IASLC 
Lung Cancer Staging Project”3 and was responsible for creating 
the 7th edition of the TNM staging system for lung cancer.4 The 
changes proposed by the IASLC were fully approved by both 
the UICC and the AJCC and are reflected in the current 7th edi-
tion of the TNM staging system for lung cancer. The 7th edition 
is currently in the process of being revised into the 8th edition.3 
This article presents the results of analyses on a newly estab-
lished database for the speciﬁc revision of the N component as 
a part of the IASLC Lung Cancer Staging Project.
In the 7th edition, lymph node involvement in lung 
cancer is categorized according to the location of the meta-
static lymph nodes as N0 (no nodes involved), N1 (ipsilat-
eral peribronchial, interlobar, or hilar node involvement), 
N2 (ipsilateral mediastinal node involvement), or N3 (con-
tralateral mediastinal, contralateral hilar, or supraclavicular 
node involvement).1,2 The UICC and AJCC in the 7th edition 
of TNM for Lung Cancer accepted the IASLC Nodal Map 
and anatomical deﬁnitions as the recommended means of 
describing regional lymph node involvement for lung can-
cers. Thus, lymph node metastasis in lung cancer has been 
graded in terms of the location of involved lymph nodes 
regardless of the number of involved lymph nodes. In the 
revision of the 6th to the 7th edition, nodal categorization 
deﬁned as N0, N1, N2, and N3 remained unchanged because 
it was highly prognostic.5
The purpose of this study is to see whether the present N 
categorization accurately reflects the prognosis, to explore if 
there is a more sophisticated method for describing the tumor 
burden in lymph nodes, using a newly established database, 
and to conclude whether the present nodal descriptors should 
be maintained or revised.
METHODS
Data Acquisition and Analysis (The 
IASLC Lung Cancer Staging Project)
The process for data acquisition and analysis of the IASLC 
Lung Cancer Staging Project database has been described else-
where.3 This database was newly created for the revision of the 
current 7th edition of the TNM staging system for lung cancer 
to the forthcoming 8th edition. The characteristics and sources 
of the whole population of the present staging project have been 
described in detail elsewhere.3 In brief, the new database for the 
revision toward 8th edition consists of 94,708 patients who were 
diagnosed with non–small-cell lung cancer (NSCLC) and small-
cell lung cancer from 1999 to 2010. This databases was composed 
of established databases from various sources (90,041 patients) and 
cases from an electronic data capture system developed by Cancer 
Research And Biostatistics in Seattle, WA (4667 patients). The 
geographic distribution of the origin of the data was as follows: 
46,560 patients from Europe, 41,705 from Asia, 4660 from North 
America, 1593 from Australia, and 190 from South America. 
These new data came from 35 sources in 16 countries. Among 
these patients, 17,552 with an unknown or different histology 
and incomplete stage information were excluded, and the remain-
ing 77,165 patients (70,976 patients with NSCLC and 6189 with 
small-cell lung cancer) were used as subjects for further analyses.
Among 70,976 patients with NSCLC, data on the “N 
component” were available in 38,910 (54.8%) patients for 
cN status and in 31,426 (44.3%) patients for pN status. The 
data source and the distribution of the cN and pN status are 
shown in Tables 1 and 2, respectively. Japan submitted the 
most data, which consisted of 23,012 (59.1%) patients for cN 
status and 23,463 (74.7%) patients for pN status, in which the 
“Naruke-Japanese map” was exclusively used to designate 
the location of metastatic lymph nodes and to determine the 
nodal status.6 In the rest of the world, the Mountain–Dresler 
modiﬁcation of the American Thoracic Society (MDATS) was 
mainly used.7 In 2009, the new international lymph node map 
(IASLC map) was promulgated by the IASLC as a part of the 





N0 N1 N2 N3 Min Median Max
Denmark 6435 845 2690 1390 11,360 4 27 124
EDC 1243 182 402 277 2104 <1 22 125
Japan 1999 8497 918 1540 79 11,034 1 66 83
Japan 2002 450 200 725 391 1766 1 16 87
Japan 2004 8501 683 985 43 10,212 1 62 88
MSKCC 535 97 198 31 861 1 80 122
Prince Charles 88 13 24 6 131 28 34 39
Sydney 14 1 3 0 18 49 59 98
TurkeyG 563 168 577 116 1424 <1 65 73
Total 26,326 3107 7144 2333 38,910 <1 61 125
EDC, electronic data capture.
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activities of the IASLC Lung Cancer Staging Project for the 
7th edition, but it was seldom used for the cases in the pres-
ent database.8 More precisely, surgical cases from Japan were 
staged according to the Naruke lymph node map adopted by 
the Japan Lung Cancer Society as the ofﬁcial staging map. 
Many surgical cases from other countries seemed to be staged 
according to MDATS. There are some differences in the deﬁ-
nition of lymph node stations near the border between N1 and 
N2 lymph node regions.8 The main discrepancy between the 
two lymph node maps is that the Naruke map considers lymph 
nodes in the subcarinal space along the inferior border of the 
main stem bronchus to be station 10 (hence, N1), whereas 
these are considered as station 7 (and, therefore, N2) in the 
MDATS map. This difference in the anatomical deﬁnition of 
each lymph node station might have influenced the nodal cat-
egorization. However, with the database collected, there was 
no way to reasonably reconcile or amend such discrepancies.
Statistical Methodology
Survival was measured from the date of diagnosis for 
clinically staged data and from the date of surgery for pathologi-
cally staged data. Survival analyses were performed according 
to clinical and pathological nodal categories regardless of the 
T category and also within the different T categories. In addi-
tion, survival was analyzed according to the number of involved 
pathological nodal stations. For this staging project, the informa-
tion on the number of metastatic nodes, not stations, was not pro-
vided outside of the cases submitted through the electronic data 
capture. Survival was calculated by the Kaplan–Meier method. 
Prognostic groups were assessed by a Cox regression analysis 
adjusted for histopathological type, sex, age, and geographic 
region, using the SAS System for Windows, version 9.2.
RESULTS
Overall Survival According to 
Clinical N (cN) Categories
Data on overall survival and cN status were available for 
38,910 T-any M0 patients. Figure 1 shows the overall survival 
for all cases according to the clinical N category. The 5-year 
survival rates by cN status were 60% (N0), 37% (N1), 23% 
(N2), and 9% (N3). For all comparisons, the differences in 
survival between neighboring cN statuses were statistically 
signiﬁcant (between cN0 and cN1, p < 0.0001; between cN1 
and cN2, p < 0.0001; between cN2 and cN3, p < 0.0001). 
Survival according to the cN status was further analyzed 
within each T category (T1–4, Fig. 2). Within each T category, 
the different cN categories showed a difference in prognosis, 
especially neighboring cN statuses, for T1 and T2 tumors. In 
the T3 and T4 tumors, cN1 was not statistically different from 
cN0. However, the comparisons between cN1 and cN2, as well 
as between cN2 and cN3, were signiﬁcant.
Overall Survival According to 
Pathological N Categories
Data on overall survival and pN status were available 
for 26,326 T-any M0 patients. Figure 3 shows the survival 
curves of patients with complete or incomplete resection (any 
R resection) and those with complete (R0) resection only. For 
both of these different R settings, the differences in survival 





N0 N1 N2 N3 Min Median Max
Belgrade 10 54 24 0 88 6 42 70
EDC 1002 218 189 21 1430 <1 23 125
Japan 1999 7717 1296 1855 100 10,968 1 66 83
Japan 2002 2994 386 401 11 3792 1 73 90
Japan 2004 6662 726 1296 19 8703 1 62 77
Korea 933 270 222 1 1426 60 87 139
MDACC 1233 260 212 0 1705 <1 42 120
MSKCC 451 74 60 1 586 1 79 110
Norway 1193 369 145 1 1708 8 55 96
Sydney 743 158 118 1 1020 <1 69 139
Total 22,938 3811 4522 155 31,426 <1 64 139
EDC, electronic data capture; MDACC, M. D. Anderson Cancer Center; MSKCC, Memorial Sloan-Kettering Cancer Center.
fIGURE 1. Survival curves for cN0, cN1, cN2, and cN3, 
T-any M0 tumors. The differences of survival between neigh-
boring categories are all statistically significant (p values: 
between cN0 and cN1, p < 0.0001; between cN1 and cN2, 
 p < 0.0001; between cN2 and cN3, p < 0.0001).
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fIGURE 2. Survival curves for cN0, cN1, cN2, and cN3 according to T categories (T1–4). The differences in survival between 
neighboring categories are all statistically significant.
fIGURE 3. Survival curves for pN0, 
pN1, pN2, and pN3, T-any M0 
tumors according to R0 and any R 
settings. For both settings, the dif-
ferences in survival between neigh-
boring categories are all statistically 
significant (for a R0 setting: between 
pN0 and pN1, p < 0.0001; between 
pN1 and pN2, p < 0.0001; between 
pN2 and pN3, p = 0.0007, for any R 
setting: between pN0 and pN1,  
p < 0.0001; between pN1 and pN2, 
p < 0.0001; between pN2 and pN3, 
p < 0.0001).
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between neighboring pN categories were all statistically sig-
niﬁcant. The 5-year survival rates according to the pN status 
for R0 and any R resections were 75% and 75% (N0), 50% 
and 49% (N1), 38% and 36% (N2), and 32% and 20% (N3), 
respectively. The results clearly showed that pN status reflects 
the prognosis of patients after resection regardless of the R 
status (for a R0 setting: between pN0 and pN1, p < 0.0001; 
between pN1 and pN2, p < 0.0001; between pN2 and pN3, 
p = 0.0012 and for any R setting but adjusting for R0 status: 
between pN0 and pN1, p < 0.0001; between pN1 and pN2, p < 
0.0001; between pN2 and pN3, p < 0.0001). Survival accord-
ing to pN status was further analyzed within each T category 
(Fig. 4). For all T categories except T4 tumor, there was a 
difference in prognosis between neighboring pN categories. 
(The difference between the small number of pN3 cases and 
pN2 was not signiﬁcant in T1, T2, or T4.) In T4, the survival 
curves of pN1 and pN2 overlapped during the ﬁrst 2 years of 
follow-up, and then separated, with pN2 showing worse sur-
vival than pN1, although the difference was not signiﬁcant. 
However, both showed signiﬁcantly worse survival than pN0. 
Figure 5 shows the survival curves according to the pN status 
for the four geographical regions: Asia (n = 23,636, 79.5%), 
Europe (n = 2479, 8.3%), North/South America (n = 2644, 
8.9%), and Australia (n = 969, 3.3%). As such, the data size 
submitted for this study was quite different for the four geo-
graphical regions. Regardless of the geographic location, the 
pN category well reflected the prognosis. However, there were 
important differences in 5-year survival rates according to the 
geographic region, especially for the pN0 and pN1 categories. 
The 5-year survival rates for pN0 by geographic region are 
79% for Asia, 54% for Europe, 67% for North/South America, 
and 58% for Australia. There was a 25% difference between 
Asia and Europe. The 5-year survival rates for pN1 by geo-
graphic region are 54% for Asia, 34% for Europe, 48% for 
North/South America, and 41% for Australia. Again, there 
was almost a 20% difference between Asia and Europe. For 
higher nodal categories, the difference in survival gradually 
diminished.
Further analyses were performed to explore the prog-
nostic impact of combining the present nodal categories and 
the number of involved lymph node stations in T-any M0 
patients for whom we had complete information on pN cat-
egories. According to the number of involved lymph node 
stations (single versus multiple), pN categories were further 
subdivided: pN1 was divided into pN1 single (pN1a) and pN1 
multiple (pN1b) and pN2 was divided into pN2 single (pN2a) 
and pN2 multiple (pN2b). The survival curves for pN1a, 
pN1b, pN2a, and pN2b are shown in Figure 6. Regardless 
fIGURE 4. Survival curves for pN0, pN1, pN2, and pN3 in T1–4 M0 R0 resected tumors. The differences in survival between 
neighboring categories are all statistically significant. In T4, the differences in the survival curves among the neighboring pN 
categories are diminished.
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fIGURE 5. Survival curves for pN0, pN1, pN2, and pN3 T-any M0, R0 resected tumors according to geographic sources of data.
fIGURE 6. Exploratory analyses of 
survival in pN1 and pN2 according 
to the number of metastatic nodal 
stations (single versus multiple) for 
R0 and any R settings (T-any M0). 
The pN1 category is divided into 
pN1 single (N1a) and pN1 multiple 
(N1b). The pN2 category is further 
divided into pN2 single (N2a) and 
pN2 multiple (N2b). Despite their 
different categories, the survival 
curves for pN1b and pN2a overlap, 
with 5-year survival rates of 50% and 
49% for R0 resection, respectively.
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of the R status, the survival curves of pN1b and pN2a over-
lapped, with no difference in survival, whereas the differences 
between pN1a and pN1b, and between pN2a and pN2b, were 
statistically signiﬁcant. The presence of skip metastasis was 
further taken into consideration: pN2a was divided into pN2 
single with skip (no pN1 involvement, pN2a1), pN2 single 
without skip (pN1 involvement as well, pN2a2), and pN2b. 
The survival curves for pN1a, pN1b, pN2a1, pN2a2, and 
pN2b are shown in Figure 7. There was a statistically signiﬁ-
cant difference in survival between pN2a1 and pN2a2, as well 
as between pN2a2 and pN2b. However, there was no signiﬁ-
cant difference in prognosis between pN1b and pN2a1. These 
results indicated that the prognosis of pN2a1 without nodal 
involvement in N1 region (skip metastasis) was close to that 
of pN1b without nodal involvement in N2 region.
DISCUSSION
Among the three components in the TNM classiﬁca-
tion for lung cancer, the nodal component (N) is of particular 
concern not only to surgeons, but also to radiation oncolo-
gists and medical oncologists because metastasis to a speciﬁc 
lymph node site (station or zone) is an important determinant 
in establishing the “stage” of the patient and the optimal thera-
peutic modality, sometimes in combination. One of the most 
important issues in the thoracic oncology is how to accurately 
describe metastasis to locoregional lymph node stations. The 
7th edition staging system deﬁnes the nodal status as N0 (no 
nodes involved), N1 (peribronchial, interlobar, or hilar node 
involvement), N2 (ipsilateral mediastinal node involvement), 
or N3 (contralateral mediastinal, contralateral hilar, or supra-
clavicular node involvement) depending solely on the loca-
tion of the metastatic lymph nodes. The deﬁnition of nodal 
categorization was not changed in the last revision from the 
6th to the 7th edition. More importantly, with regard to lung 
cancer, the principle has been maintained that the nodal status 
is based on the anatomical location of the metastatic lymph 
node in the thorax and not on the number of the metastatic 
lymph nodes (nN). Among tumors at various sites, the lung is 
the only site in which nodal categorization is determined by 
location alone, regardless of the tumor burden in the involved 
lymph nodes.1,2 In other organs, the nodal status is determined 
according to nN (gastrointestinal tract, breast, and kidney), 
the combination of nN and size (head and neck), or simply 
the presence of regional lymph node metastasis (prostate and 
cervical uterus). Despite its similar location in the thoracic 
cavity and the fact that it shares common lymphatic pathways, 
nodal categorization for esophageal cancer is based solely 
on nN: N0, no nodal involvement; N1, metastasis in 1 and 
2 lymph nodes; N2, metastasis in 3 to 6 lymph nodes; N3, 
metastasis in 7 or more regional lymph nodes. This principle 
in lung cancer has been widely accepted because the lymph 
node location can be easily determined on computed tomogra-
phy or positron emission tomography, it is prognostic, and this 
categorization is anatomically reasonable from the perspective 
of a lymphatic pathway from the lung parenchyma through the 
hilum, mediastinum, and supraclavicular fossa.
The possibility of nN instead of location-based cN or pN 
for nodal categorization in lung cancer has been studied in the 
past. Wei et al.9 and Saji et al.10 compared the two categoriza-
tions, by location (pN) and number of metastatic lymph nodes 
(nN), and showed that nN is a better prognostic determinant 
than the location-based pN classiﬁcation. Indeed, the present 
data also demonstrated that the prognoses of pN1 and pN2 
were reversed when the number of metastatic lymph node sta-
tions and the absence/presence of skip metastasis were taken 
into consideration. Patients with pN2 metastasis at a single 
lymph node station without hilar involvement (skip metastasis) 
had better survival than those with pN1 metastasis at multiple 
fIGURE 7. Exploratory analyses of 
survival for pN1 and pN2 according 
to the number of metastatic nodal 
stations (single versus multiple, skip 
metastasis versus nonskip metastasis) 
for R0 and any R settings (T-any M0). 
pN1 is divided into pN1 single (N1a) 
and pN1 multiple (N1b). The pN2 
category is further divided into pN2 
single with skip metastasis (N2a1), 
pN2 single with N1 metastasis 
(N2a2), and pN2-multiple (N2b). 
There was no statistically significant 
difference in survival between pN1b 
and pN2a1, with 5-year survival rates 
of 50% and 52% for R0 resection, 
respectively.
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stations. In the location-based categorization, the tumor burden 
at regional lymph nodes is not reflected at all. Thus, a small, 
even microscopic, metastasis at a single #10 node and gross 
involvement of multiple lymph nodes of 2 cm in size at stations 
#10 and #11 belong to the same category as N1. This might 
have accounted for the small inversion of the prognosis. On the 
other hand, Wei et al.9 addressed the problems of nN in practi-
cal use. For example, it is quite difﬁcult to determine nN before 
treatment by low-resolution imaging diagnosis. On a positron 
emission tomographic image, metastatic nodes are not clearly 
separated for accurate counting. This difﬁculty in counting the 
number of metastatic nodes directly affects the stage of the 
patient. Unfortunately, the present database did not include 
information regarding the number of involved nodes, and it 
was not possible for us to assess the value of nN. Information 
regarding the involved stations, not nodes, and thus the possi-
bility of more accurate nodal staging was available from only a 
limited number of institutions. Therefore, we recommend that 
physicians should prospectively record both nN and the location 
using the IASLC nodal map and anatomical deﬁnitions for use 
in the future analysis. As the number of metastatic lymph nodes 
is used for nodal categorization in many organs, the need to 
collect this information should be addressed for future analysis.
The IASLC Lung Cancer Staging Project has been very 
successful in revising the staging system through a rigorous 
scientiﬁc process. However, the nature of the data needs to be 
addressed from a statistical perspective. As noted previously, 
information on the N categorization was available for 38,910 and 
31,426 patients for analyses of cN and pN status, respectively. 
However, there was considerable imbalance in the origin of the 
data for the present staging project. Japan submitted the larg-
est amount of data on N: data regarding cN for 23,012 patients 
(59.1%) and regarding pN for 23,463 patients (74.7%). Most of 
the data, especially those for pN status, came from Japan. On the 
other hand, only a small fraction of data, 3.6% (cN) and 8.7% 
(pN), came from North/South America. As noted above, two dif-
ferent lymph node maps were used when these databases were 
constructed, and the use of different maps might have caused a 
stage shift, with a different prognosis for the same pN status. The 
present analysis of N was mostly an evaluation of nodal catego-
rization based upon Japanese-Naruke map. Therefore, it might 
not be appropriate to conclude that nodal categorization accord-
ing to MDATS is also prognostic. We must fully understand the 
imbalance in the data source with respect to N to interpret these 
results. Future revisions should be based on a well-balanced, 
truly international large data set using the uniﬁed, internationally 
recognized nodal map developed by the IASLC and the accom-
panying anatomical deﬁnitions.8 Global collaboration for the 
collection of well-balanced data from all over the world needs to 
be addressed for the future revisions.
Lastly, the method used to evaluate harvested lymph nodes 
needs to be standardized. It has been noted that the incomplete 
retrieval of lymph nodes from a resected specimen seriously 
affects nodal categorization.11 According to the TNM rules, at 
least six lymph nodes need to be removed, three from N1 and 
three from N2 stations. This is the minimum requirement for 
a diagnosis of N0 when lymph nodes are negative.1 However, 
there is still a question regarding the minimum number of lymph 
nodes that should be assessed pathologically. Usually, when sys-
tematic lymph node dissection is performed, the lymph nodes 
are dissected en bloc together with surrounding adipose tissue 
as a lump. Ideally, pathologists or surgeons should remove these 
nodes out as distinct nodes. Otherwise, some of the nodes can 
be missed without undergoing a pathological assessment. Future 
staging system should provide guidelines or suggestions regard-
ing a standardized method for evaluating dissected/removed 
lymph nodes, as well as a formula for reporting.
The present analyses of the 1999 to 2010 IASLC data-
base with respect to the N component have shown that the 
present N categories are still useful for distinguishing between 
tumors with signiﬁcantly different prognoses in both clinical 
and pathological settings. In addition, the number of involved 
nodal stations was found to have prognostic impact, although 
this ﬁnding was derived from pathological staging and could 
not be validated in clinical staging. Therefore, while this ﬁnd-
ing has intrinsic value for reﬁning the postoperative prognosis 
for individual patients and for creating postoperative prognos-
tic groups, it could not be used to recommend modiﬁcations 
to the present N descriptors because, in principle, clinical and 
pathological descriptors should be the same. However, in the 
7th edition of the TNM classiﬁcation of malignant tumors, 
cancers of the breast and penis are exceptions to this rule and 
have different descriptors for the clinical and pathological N 
categories. Fixation and mobility are used for clinical stag-
ing, and the number of involved lymph nodes is used to deﬁne 
the pathological N categories. These two exceptions reflect the 
difﬁculty of counting the number of involved lymph nodes in 
clinical staging and, at the same time, acknowledge the impor-
tance of the number of involved lymph nodes at pathological 
staging. Because of the difﬁculty of counting the number of 
involved lymph nodes in lung cancer with the tests that are 
currently available for clinical staging and the unquestionable 
evidence that the number of involved nodes has a signiﬁcant 
prognostic impact, we may wish to seriously consider if lung 
cancer should also be an exception to the rule if robust data 
demonstrating this can be collected.
In conclusion, based on the results of the analyses of 
the new IASLC database, the IASLC Staging and Prognostic 
Factors Committee recommends the following policy regard-
ing the N component for the 8th edition of the TNM classiﬁca-
tion of lung cancer.
Recommendations
1.  The use of the N descriptors described in the 7th edi-
tion of TNM for Lung Cancer should be carried for-
ward, without changes into the 8th edition.
2.  Additional analyses suggest that the combination 
of location of metastatic nodes, nN (single station 
versus multiple stations), and absence versus pres-
ence of skip metastasis as pN0, pN1a, pN1b, pN2a1, 
pN2a2, and pN2b may give a more accurate prog-
nosis. This classiﬁcation requires prospective evalu-
ation before being considered for future revisions of 
the TNM staging system for lung cancer.
3.  The IASLC nodal map and anatomical deﬁnitions8 
should be used to describe regional lymph node 
involvement for lung cancer
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